-
The Puzzle of Pancreatic CancerPancreatic cancer remains a difficult disease to treat and is expected to be the second leading cause of U.S. cancer-related deaths by 2030. Researchers hope clinical trials and insights into the genetics of the disease will reverse the trend.
by Kendall K. Morgan
-
Medicare Coverage for Next-Generation Sequencing TestsMultigene panels that rely on next-generation sequencing are increasingly used to test for hereditary cancer risk-related mutations. The federal government aims to expand Medicare coverage for these tests.
by Ashley P. Taylor
-
For Prostate Biopsy, It’s Best to Combine Old and New MethodsUsing an older method of prostate biopsy together with MRI-targeted biopsy more accurately diagnoses prostate cancer than either method alone, a study finds.
by Kate Yandell
-
On Cancer and IdentityThe first time Liza Bernstein was diagnosed with cancer, she wouldn't allow it to be part of her identity. After her third cancer diagnosis, she became an advocate for other patients.
by Liza Bernstein
-
Despite Generic Imatinib, Cost of Treating CML Remains HighThe arrival of generic versions of the targeted therapy imatinib only modestly reduced the cost of treating chronic myelogenous leukemia patients, a study finds.
by Anna Azvolinsky
-
Nothing but TimeA father with metastatic kidney cancer embraces moments with his 3-year-old son while pondering how he'll be remembered.
by Adam P. Stern
-
When Cancer Becomes an Unwanted PriorityAmanda Rose Ferraro's leukemia diagnosis forced her to spend time at the hospital away from her 3-year-old-son. She calls focusing on her health and leaving her son “the hardest thing I have ever had to do.”
by Amanda Rose Ferraro
-
New Drugs for an Elusive Cancer TargetMedical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.
by Anna Azvolinsky
-
Clinical Trials: An African American Survivor’s ExperienceMelvin Mann benefited from joining a pivotal clinical trial for chronic myelogenous leukemia, but participation came with logistical challenges.
by Melvin Mann
-
“Congrats! You Have the ‘Good’ Cancer”Many people know thyroid cancer as a cancer type with a relatively good prognosis, but the disease still has profound effects on patients and survivors, writes thyroid cancer survivor Carly Flumer.
by Carly Flumer
Using high-dose testosterone after prostate cancer stops responding to androgen deprivation therapy can stop tumor growth.
by Sandra Gordon
Financial Screenings for People with CancerCancer patients say they want to be asked about their financial needs on a regular basis.
by Pamela Appea
Let Me Tell You a Story About the Power of Medical ResearchTen-year-old Michael Methner told his story about being diagnosed with optic nerve glioma at the AACR’s Rally for Medical Research.
by Cancer Research Catalyst
Aggressive Approach to Very Advanced Cancer Does Not Extend SurvivalStudy shows no benefit from treatment for cancers at very advanced stages of progression. Researchers urge end-of-life planning for these patients.
by Kyle Bagenstose
-
AACR Grant Propels Progress in Immunotherapy ResearchA grant from the American Association for Cancer Research (AACR) helped Marco Ruella, MD, develop a new approach to immunotherapy.
-
Self-screening for Cancer: Home Sweet HomeNew cervical cancer self-screening options and a portable blood test device could lead to changes in at-home cancer screening.
Alexis Browning
